235 related articles for article (PubMed ID: 25920446)
1. Inhibitory effects of peroxisome proliferator-activated receptor γ agonists on collagen IV production in podocytes.
Li Y; Shen Y; Li M; Su D; Xu W; Liang X; Li R
Mol Cell Biochem; 2015 Jul; 405(1-2):233-41. PubMed ID: 25920446
[TBL] [Abstract][Full Text] [Related]
2. PPAR-gamma agonist protects podocytes from injury.
Kanjanabuch T; Ma LJ; Chen J; Pozzi A; Guan Y; Mundel P; Fogo AB
Kidney Int; 2007 Jun; 71(12):1232-9. PubMed ID: 17457378
[TBL] [Abstract][Full Text] [Related]
3. Novel effects of rosiglitazone on SMAD2 and SMAD3 signaling in white adipose tissue of diabetic rats.
Beaudoin MS; Snook LA; Arkell AM; Stefanson A; Wan Z; Simpson JA; Holloway GP; Wright DC
Obesity (Silver Spring); 2014 Jul; 22(7):1632-42. PubMed ID: 24500776
[TBL] [Abstract][Full Text] [Related]
4. Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptor-gamma.
Ghosh AK; Wei J; Wu M; Varga J
Biochem Biophys Res Commun; 2008 Sep; 374(2):231-6. PubMed ID: 18627765
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-mesenchymal transition-like phenotypic changes of retinal pigment epithelium induced by TGF-β are prevented by PPAR-γ agonists.
Hatanaka H; Koizumi N; Okumura N; Kay EP; Mizuhara E; Hamuro J; Kinoshita S
Invest Ophthalmol Vis Sci; 2012 Oct; 53(11):6955-63. PubMed ID: 22956604
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition.
Reka AK; Kurapati H; Narala VR; Bommer G; Chen J; Standiford TJ; Keshamouni VG
Mol Cancer Ther; 2010 Dec; 9(12):3221-32. PubMed ID: 21159608
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models.
Gu J; Liu X; Wang QX; Guo M; Liu F; Song ZP; Zhang DD
J Mol Cell Cardiol; 2013 Dec; 65():1-8. PubMed ID: 24100253
[TBL] [Abstract][Full Text] [Related]
8. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma.
Ghosh AK; Bhattacharyya S; Lakos G; Chen SJ; Mori Y; Varga J
Arthritis Rheum; 2004 Apr; 50(4):1305-18. PubMed ID: 15077315
[TBL] [Abstract][Full Text] [Related]
9. Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts.
Koo JB; Nam MO; Jung Y; Yoo J; Kim DH; Kim G; Shin SJ; Lee KM; Hahm KB; Kim JW; Hong SP; Lee KJ; Yoo JH
BMC Gastroenterol; 2017 Jun; 17(1):73. PubMed ID: 28592228
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist inhibits collagen synthesis in human hypertrophic scar fibroblasts by targeting Smad3 via miR-145.
Zhu HY; Li C; Zheng Z; Zhou Q; Guan H; Su LL; Han JT; Zhu XX; Wang SY; Li J; Hu DH
Biochem Biophys Res Commun; 2015 Mar; 459(1):49-53. PubMed ID: 25704091
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts.
Zhang GY; Yi CG; Li X; Ma B; Li ZJ; Chen XL; Guo SZ; Gao WY
Br J Dermatol; 2009 Apr; 160(4):762-70. PubMed ID: 19120328
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts.
Guo N; Woeller CF; Feldon SE; Phipps RP
J Biol Chem; 2011 May; 286(21):18856-67. PubMed ID: 21454487
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone.
Nicola T; Ambalavanan N; Zhang W; James ML; Rehan V; Halloran B; Olave N; Bulger A; Oparil S; Chen YF
Am J Physiol Lung Cell Mol Physiol; 2011 Jul; 301(1):L125-34. PubMed ID: 21531777
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor γ agonist suppresses mast cell maturation and induces apoptosis.
Zhang Y; Li X; Fang S; Zhu Z; Yao M; Ying L; Zhu L; Ma Z; Wang W
Mol Med Rep; 2017 Aug; 16(2):1793-1800. PubMed ID: 28656266
[TBL] [Abstract][Full Text] [Related]
15. Agonists of peroxisome proliferators-activated receptors (PPAR) alpha, beta/delta or gamma reduce transforming growth factor (TGF)-beta-induced proteoglycans' production in chondrocytes.
Poleni PE; Bianchi A; Etienne S; Koufany M; Sebillaud S; Netter P; Terlain B; Jouzeau JY
Osteoarthritis Cartilage; 2007 May; 15(5):493-505. PubMed ID: 17140817
[TBL] [Abstract][Full Text] [Related]
16. Gremlin aggravates hyperglycemia-induced podocyte injury by a TGFβ/smad dependent signaling pathway.
Li G; Li Y; Liu S; Shi Y; Chi Y; Liu G; Shan T
J Cell Biochem; 2013 Sep; 114(9):2101-13. PubMed ID: 23553804
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.
Zafiriou S; Stanners SR; Saad S; Polhill TS; Poronnik P; Pollock CA
J Am Soc Nephrol; 2005 Mar; 16(3):638-45. PubMed ID: 15689403
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells.
Liu Y; Dai B; Xu C; Fu L; Hua Z; Mei C
PLoS One; 2011; 6(12):e28915. PubMed ID: 22174924
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis.
Yang HC; Ma LJ; Ma J; Fogo AB
Kidney Int; 2006 May; 69(10):1756-64. PubMed ID: 16598202
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor ɣ agonist mediated inhibition of heparanase expression reduces proteinuria.
Garsen M; Buijsers B; Sol M; Gockeln L; Sonneveld R; van Kuppevelt TH; de Graaf M; van den Born J; Kamps JAAM; van Raalte DH; van der Meer RW; Lamb HJ; Hillebrands JL; Rabelink TJ; Maciej-Hulme ML; Krenning G; Nijenhuis T; van der Vlag J
EBioMedicine; 2023 Apr; 90():104506. PubMed ID: 36889064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
